ClinicalTrials.gg

Program

huperzine A

Also written as “Huperzine A injection”, “Huperzine A Oral Solution” and “Huperzine A for Injection”.

Its studies are mostly in Brain Injuries · Sensation Disorders · Schizophrenia · Alzheimer Disease, led by 5 companies.

Furthest: phase 4, since Apr 30, 20247 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wanbangde Pharmaceutical Group32 open or runningphase 4since Apr 30, 2024Apr 27, 2024Dec 31, 2026phase 1 · NCT07784335
Biomedisyn10 open or runningphase 2since Aug 10, 2009Aug 10, 2009none ahead
Jiangsu Famous Medical Technology10 open or runningphase 4since Jul 22, 2020Jul 22, 2020none ahead
Luye Pharma Group10 open or runningphase 3since Jan 24, 2011Jan 24, 2011none ahead
Supernus Pharmaceuticals10 open or runningphase 1since May 15, 2017May 15, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 10, 2009First study: phase 2 study in SchizophreniaNew to BiomedisynBiomedisyn · NCT00963846 · 56 enrolled · United States
  2. Jan 24, 2011Luye Pharma Group’s first study: phase 3 study in Alzheimer DiseaseNew to Luye Pharma GroupLuye Pharma Group · NCT01282619 · 390 enrolled · China
  3. May 15, 2017Supernus Pharmaceuticals’ first study: phase 1 study in Epilepsy, Complex PartialNew to Supernus PharmaceuticalsSupernus Pharmaceuticals · NCT03156439 · 8 enrolled · Australia
  4. Jul 22, 2020Jiangsu Famous Medical Technology’s first study: phase 4 study in Sensation DisordersNew to Jiangsu Famous Medical TechnologyJiangsu Famous Medical Technology · NCT04509323 · 20 enrolled · China
  5. Apr 27, 2024Wanbangde Pharmaceutical Group’s first study: phase 1 study in Healthy SubjectsNew to Wanbangde Pharmaceutical GroupWanbangde Pharmaceutical Group · NCT06570655 · 12 enrolled · China
  6. Apr 30, 2024Phase 4 study in Cognitive Impairment After Brain InjuryWanbangde Pharmaceutical Group · NCT06704334 · 50 planned · China
  7. Aug 13, 2026Phase 1 study in HealhtyWanbangde Pharmaceutical Group · NCT07784335 · 40 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in HealhtyWanbangde Pharmaceutical Group · NCT07784335
  2. Dec 31, 2026Primary completion: phase 4 study in Cognitive Impairment After Brain InjuryWanbangde Pharmaceutical Group · NCT06704334

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
DonepezilruleEisaiphase 483
benzgalantamine gluconaterulealpha-cognition-incphase 41
Z 338ruleZeria Pharmaceuticalphase 312

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07784335Healhty · China1Not yet recruitingWanbangde Pharmaceutical GroupDec 31, 202640
NCT06704334Cognitive Impairment After Brain Injury · China4RecruitingWanbangde Pharmaceutical GroupDec 31, 202650
NCT06570655Healthy Subjects · China1CompletedWanbangde Pharmaceutical GroupJun 20, 202412
NCT04509323Sensation Disorders · China4UNKNOWNJiangsu Famous Medical TechnologyFeb 28, 202120
NCT03156439Epilepsy, Complex Partial · Australia1CompletedSupernus PharmaceuticalsSep 30, 20178
NCT01282619Alzheimer Disease · China3UNKNOWNLuye Pharma GroupJun 2012390
NCT00963846Schizophrenia · United States2CompletedBiomedisynDec 201256

How it is read

Names in the registry

  • “Huperzine A injection”, 3 entries
  • “Huperzine A Oral Solution”, 1 entry
  • “Huperzine A for Injection”, 1 entry
  • “BIS-001 ER”, 1 entry
  • “huperzine 0.2 mg BID”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.